NCT07408635 2026-02-13
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
University of Kentucky
Instituto do Cancer do Estado de São Paulo
Pfizer